{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:47:56Z","timestamp":1784000876135,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Joint Funds for the innovation of science and Technology, Fujian province","award":["2019Y9047"],"award-info":[{"award-number":["2019Y9047"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["SQ2020YFF0426513"],"award-info":[{"award-number":["SQ2020YFF0426513"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Circular RNAs (circRNAs) are a class of highly stable and closed-loop noncoding RNA that are involved in the occurrence and development of hepatocellular carcinoma (HCC). However, little is known about the therapeutic role of circRNAs in HCC. We found that high circ_0058051 expression was negatively correlated with the prognosis of HCC patients. Circ_0058051 knockdown attenuated the proliferation and colony formation, meanwhile inhibited migration of HCC cells. Circ_0058051 may be used as a target for HCC gene therapy. We synthesized a novel small interfering RNA (siRNA) delivery system, PEG-PCL-PEI-C14-SPIONs (PPPCSs), based on superparamagnetic iron oxide nanoparticles (SPIONs). PPPCSs protected the siRNA of circ_0058051 from degradation in serum and effectively delivered siRNA into SMMC-7721 cells. Meanwhile, intravenous injection of the PPPCSs\/siRNA complex could inhibit tumor growth in the subcutaneous tumor model. In addition, the nanocomposite is not toxic to the organs of nude mice. The above results show that PPPCSs\/si-circ_0058051 complex may provide a novel and promising method of HCC treatment.<\/jats:p>\n                <jats:p><jats:bold>Graphical abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s13346-022-01237-z","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T16:03:10Z","timestamp":1663344190000},"page":"782-794","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Magnetically responsive nanoplatform targeting circRNA circ_0058051 inhibits hepatocellular carcinoma progression"],"prefix":"10.1007","volume":"13","author":[{"given":"Song","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niangmei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0055-3989","authenticated-orcid":false,"given":"Bixing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"issue":"3","key":"1237_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"1237_CR2","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-17-0289","volume":"24","author":"M Inarrairaegui","year":"2018","unstructured":"Inarrairaegui M, Melero I, Sangro B. Immunotherapy of hepatocellular carcinoma: facts and hopes. Clin Cancer Res. 2018;24(7):1518\u201324.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1237_CR3","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/onc.2017.361","volume":"37","author":"LS Kristensen","year":"2018","unstructured":"Kristensen LS, Hansen TB, Veno MT, Kjems J. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene. 2018;37(5):555\u201365.","journal-title":"Oncogene"},{"issue":"6","key":"1237_CR4","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.jhep.2018.01.012","volume":"68","author":"J Yu","year":"2018","unstructured":"Yu J, Xu QG, Wang ZG, et al. Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma. J Hepatol. 2018;68(6):1214\u201327.","journal-title":"J Hepatol"},{"issue":"1","key":"1237_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12943-020-01213-6","volume":"19","author":"XY Huang","year":"2020","unstructured":"Huang XY, Zhang PF, Wei CY, et al. Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p\/snail\/DPP4 axis. Mol Cancer. 2020;19(1):92.","journal-title":"Mol Cancer"},{"key":"1237_CR6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.omtn.2020.09.007","volume":"22","author":"B Ding","year":"2020","unstructured":"Ding B, Fan W, Lou W. hsa_circ_0001955 Enhances in vitro proliferation, migration, and invasion of HCC cells through miR-145-5p\/NRAS axis. Mol Ther Nucleic Acids. 2020;22:445\u201355.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"1237_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13046-020-01576-0","volume":"39","author":"LN Song","year":"2020","unstructured":"Song LN, Qiao GL, Yu J, et al. Hsa_circ_0003998 promotes epithelial to mesenchymal transition of hepatocellular carcinoma by sponging miR-143-3p and PCBP1. J Exp Clin Cancer Res. 2020;39(1):114.","journal-title":"J Exp Clin Cancer Res"},{"key":"1237_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.gde.2017.11.007","volume":"48","author":"IL Patop","year":"2018","unstructured":"Patop IL, Kadener S. circRNAs in cancer. Curr Opin Genet Dev. 2018;48:121\u20137.","journal-title":"Curr Opin Genet Dev"},{"key":"1237_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2015.23","volume":"4","author":"JK Lam","year":"2015","unstructured":"Lam JK, Chow MY, Zhang Y, Leung SW. siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids. 2015;4: e252.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"36","key":"1237_CR10","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1200\/JCO.2013.55.0376","volume":"32","author":"B Schultheis","year":"2014","unstructured":"Schultheis B, Strumberg D, Santel A, et al. First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J Clin Oncol. 2014;32(36):4141\u20138.","journal-title":"J Clin Oncol"},{"key":"1237_CR11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.omtn.2018.02.005","volume":"11","author":"H Javanbakht","year":"2018","unstructured":"Javanbakht H, Mueller H, Walther J, et al. Liver-targeted anti-HBV single-stranded oligonucleotides with locked nucleic acid potently reduce HBV gene expression in vivo. Mol Ther Nucleic Acids. 2018;11:441\u201354.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1237_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.595819","volume":"11","author":"JL Katzmann","year":"2020","unstructured":"Katzmann JL, Gouni-Berthold I, Laufs U. PCSK9 inhibition: insights from clinical trials and future prospects. Front Physiol. 2020;11:595819.","journal-title":"Front Physiol"},{"issue":"15","key":"1237_CR13","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","volume":"78","author":"SM Hoy","year":"2018","unstructured":"Hoy SM. Patisiran: first global approval. Drugs. 2018;78(15):1625\u201331.","journal-title":"Drugs"},{"issue":"6","key":"1237_CR14","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/mt.2015.14","volume":"23","author":"M Barve","year":"2015","unstructured":"Barve M, Wang Z, Kumar P, et al. Phase 1 trial of Bi-shRNA STMN1 BIV in refractory cancer. Mol Ther. 2015;23(6):1123\u201330.","journal-title":"Mol Ther"},{"issue":"16","key":"1237_CR15","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319.","journal-title":"N Engl J Med"},{"issue":"1","key":"1237_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12943-021-01443-2","volume":"20","author":"W Mao","year":"2021","unstructured":"Mao W, Wang K, Xu B, et al. ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma. Mol Cancer. 2021;20(1):142.","journal-title":"Mol Cancer"},{"issue":"2","key":"1237_CR17","first-page":"187","volume":"85","author":"K Gavrilov","year":"2012","unstructured":"Gavrilov K, Saltzman WM. Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med. 2012;85(2):187\u2013200.","journal-title":"Yale J Biol Med"},{"issue":"6","key":"1237_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421\u201346.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"1237_CR19","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.apsb.2020.10.005","volume":"10","author":"NB Charbe","year":"2020","unstructured":"Charbe NB, Amnerkar ND, Ramesh B, et al. Small interfering RNA for cancer treatment: overcoming hurdles in delivery. Acta Pharm Sin B. 2020;10(11):2075\u2013109.","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"1237_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11060-010-0389-0","volume":"103","author":"K Maier-Hauff","year":"2011","unstructured":"Maier-Hauff K, Ulrich F, Nestler D, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. 2011;103(2):317\u201324.","journal-title":"J Neurooncol"},{"key":"1237_CR21","doi-asserted-by":"crossref","unstructured":"Dulinska-Litewka J, Lazarczyk A, Halubiec P, Szafranski O, Karnas K, Karewicz A. Superparamagnetic iron oxide nanoparticles-current and prospective medical applications. Materials (Basel). 2019;12(4).","DOI":"10.3390\/ma12040617"},{"issue":"1","key":"1237_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2217\/nnm-2016-0316","volume":"12","author":"L Zhu","year":"2017","unstructured":"Zhu L, Zhou Z, Mao H, Yang L. Magnetic nanoparticles for precision oncology: theranostic magnetic iron oxide nanoparticles for image-guided and targeted cancer therapy. Nanomedicine (Lond). 2017;12(1):73\u201387.","journal-title":"Nanomedicine (Lond)"},{"key":"1237_CR23","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jconrel.2020.02.035","volume":"321","author":"FQ Hour","year":"2020","unstructured":"Hour FQ, Moghadam AJ, Shakeri-Zadeh A, Bakhtiyari M, Shabani R, Mehdizadeh M. Magnetic targeted delivery of the SPIONs-labeled mesenchymal stem cells derived from human Wharton\u2019s jelly in Alzheimer\u2019s rat models. J Control Release. 2020;321:430\u201341.","journal-title":"J Control Release"},{"key":"1237_CR24","first-page":"1701","volume":"11","author":"IM Pongrac","year":"2016","unstructured":"Pongrac IM, Pavicic I, Milic M, et al. Oxidative stress response in neural stem cells exposed to different superparamagnetic iron oxide nanoparticles. Int J Nanomedicine. 2016;11:1701\u201315.","journal-title":"Int J Nanomedicine"},{"issue":"sup1","key":"1237_CR25","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1080\/21691401.2018.1439839","volume":"46","author":"N Asadi","year":"2018","unstructured":"Asadi N, Annabi N, Mostafavi E, et al. Synthesis, characterization and in vitro evaluation of magnetic nanoparticles modified with PCL-PEG-PCL for controlled delivery of 5FU. Artif Cells Nanomed Biotechnol. 2018;46(sup1):938\u201345.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"1237_CR26","doi-asserted-by":"crossref","unstructured":"Sorasitthiyanukarn FN, Muangnoi C, Thaweesest W, et al. Polyethylene glycol-chitosan oligosaccharide-coated superparamagnetic iron oxide nanoparticles: a novel drug delivery system for curcumin diglutaric acid. Biomolecules. 2020;10(1).","DOI":"10.3390\/biom10010073"},{"issue":"3","key":"1237_CR27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/wnan.81","volume":"2","author":"T Tokatlian","year":"2010","unstructured":"Tokatlian T, Segura T. siRNA applications in nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2(3):305\u201315.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"1237_CR28","doi-asserted-by":"crossref","unstructured":"Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am. 2010;24(4):899\u2013919, viii.","DOI":"10.1016\/j.idc.2010.07.004"},{"key":"1237_CR29","doi-asserted-by":"publisher","first-page":"9875","DOI":"10.2147\/IJN.S277845","volume":"15","author":"H Zhang","year":"2020","unstructured":"Zhang H, Men K, Pan C, et al. Treatment of colon cancer by degradable rrPPC nano-conjugates delivered STAT3 siRNA. Int J Nanomedicine. 2020;15:9875\u201390.","journal-title":"Int J Nanomedicine"},{"key":"1237_CR30","doi-asserted-by":"crossref","unstructured":"Sajid MI, Moazzam M, Kato S, Yeseom Cho K, Tiwari RK. Overcoming barriers for siRNA therapeutics: from bench to bedside. Pharmaceuticals (Basel). 2020;13(10).","DOI":"10.3390\/ph13100294"},{"issue":"1","key":"1237_CR31","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41392-020-00375-5","volume":"5","author":"J Xu","year":"2020","unstructured":"Xu J, Ji L, Liang Y, et al. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduct Target Ther. 2020;5(1):298.","journal-title":"Signal Transduct Target Ther"},{"issue":"19","key":"1237_CR32","first-page":"9924","volume":"24","author":"BC Cedric","year":"2020","unstructured":"Cedric BC, Souraka TDM, Feng YL, Kisembo P, Tu JC. CircRNA ZFR stimulates the proliferation of hepatocellular carcinoma through upregulating MAP2K1. Eur Rev Med Pharmacol Sci. 2020;24(19):9924\u201331.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"1237_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13046-020-01691-y","volume":"39","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Zhou J, Zhao J, et al. The U2AF2 \/circRNA ARF1\/miR-342-3p\/ISL2 feedback loop regulates angiogenesis in glioma stem cells. J Exp Clin Cancer Res. 2020;39(1):182.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1237_CR34","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu B, Zhong L, Weng Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5(1):101.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"1237_CR35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","volume":"80","author":"LJ Scott","year":"2020","unstructured":"Scott LJ. Givosiran: first approval. Drugs. 2020;80(3):335\u20139.","journal-title":"Drugs"},{"issue":"3","key":"1237_CR36","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","volume":"81","author":"YN Lamb","year":"2021","unstructured":"Lamb YN. Inclisiran: first approval. Drugs. 2021;81(3):389\u201395.","journal-title":"Drugs"},{"key":"1237_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2020.102239","volume":"29","author":"MA Subhan","year":"2020","unstructured":"Subhan MA, Torchilin VP. siRNA based drug design, quality, delivery and clinical translation. Nanomedicine. 2020;29:102239.","journal-title":"Nanomedicine"},{"key":"1237_CR38","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.2147\/IJN.S162939","volume":"13","author":"Q Sun","year":"2018","unstructured":"Sun Q, Wang X, Cui C, Li J, Wang Y. Doxorubicin and anti-VEGF siRNA co-delivery via nano-graphene oxide for enhanced cancer therapy in vitro and in vivo. Int J Nanomedicine. 2018;13:3713\u201328.","journal-title":"Int J Nanomedicine"},{"key":"1237_CR39","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3389\/fimmu.2019.01279","volume":"10","author":"D Hildebrand","year":"2019","unstructured":"Hildebrand D, Metz-Zumaran C, Jaschkowitz G, Heeg K. Silencing SOCS1 via Liposome-packed siRNA sustains TLR4-ligand adjuvant. Front Immunol. 2019;10:1279.","journal-title":"Front Immunol"},{"key":"1237_CR40","doi-asserted-by":"publisher","first-page":"15130","DOI":"10.1038\/ncomms15130","volume":"8","author":"Y Lei","year":"2017","unstructured":"Lei Y, Tang L, Xie Y, et al. Gold nanoclusters-assisted delivery of NGF siRNA for effective treatment of pancreatic cancer. Nat Commun. 2017;8:15130.","journal-title":"Nat Commun"},{"key":"1237_CR41","doi-asserted-by":"crossref","unstructured":"Liu J, Zhang Y, Zeng Q, et al. Delivery of RIPK4 small interfering RNA for bladder cancer therapy using natural halloysite nanotubes. Sci Adv. 2019;5(9):eaaw6499.","DOI":"10.1126\/sciadv.aaw6499"},{"issue":"2","key":"1237_CR42","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1021\/mp7001285","volume":"5","author":"TK Jain","year":"2008","unstructured":"Jain TK, Reddy MK, Morales MA, Leslie-Pelecky DL, Labhasetwar V. Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Mol Pharm. 2008;5(2):316\u201327.","journal-title":"Mol Pharm"},{"issue":"40","key":"1237_CR43","doi-asserted-by":"publisher","first-page":"15226","DOI":"10.1039\/C7NR05429G","volume":"9","author":"CM Sims","year":"2017","unstructured":"Sims CM, Hanna SK, Heller DA, et al. Redox-active nanomaterials for nanomedicine applications. Nanoscale. 2017;9(40):15226\u201351.","journal-title":"Nanoscale"},{"issue":"9","key":"1237_CR44","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1002\/1878-0261.12544","volume":"13","author":"J Li","year":"2019","unstructured":"Li J, You S, Zhang S, et al. Elevated N-methyltransferase expression induced by hepatic stellate cells contributes to the metastasis of hepatocellular carcinoma via regulation of the CD44v3 isoform. Mol Oncol. 2019;13(9):1993\u20132009.","journal-title":"Mol Oncol"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-022-01237-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-022-01237-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-022-01237-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T19:41:16Z","timestamp":1675280476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-022-01237-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1237"],"URL":"https:\/\/doi.org\/10.1007\/s13346-022-01237-z","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]},"assertion":[{"value":"3 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All institutional and national guidelines for the care and use of laboratory animals were followed. All human HCC tumor samples were obtained and used under informed written patient consent and local ethical committee approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors provided consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}